Screening for Postpartum Depression—Research Review and Update

"Postpartum depression remains vastly under-diagnosed and under-treated, despite widespread consensus regarding its prevalence and potentially devastating consequences," write Dr. Erin Smith of Western Psychiatric Institute and Clinic of University of Pittsburgh Medical Center and colleagues. They analyze current research evidence on PPD screening from the psychiatrist's perspective.

Screening for PPD—What Psychiatrists Need to KnowApproximately 14.5 percent of women will experience a new episode of depression during pregnancy or in the initial months after delivery, studies report. Yet many cases of PPD go undiagnosed, and nearly half of diagnosed cases go untreated. After delivery, PPD can impede bonding with the newborn, adversely affecting the child's behavioral and emotional development.

Major obstetrics and pediatrics specialty groups recommend screening for PPD. But while there's an extensive body of research on PPD screening, it's mainly targeted to the primary care practitioners who provide routine care for mothers and infants. Dr. Smith and collages review the evidence on screening tools, timing, and location—directed toward psychiatrics and other mental health professionals involved in treating PPD.

Postpartum depression is defined as symptoms of major depression developing within the first month after delivery, but the risk can persist for much longer. A key issue is distinguishing PPD from "maternity blues"—short episodes of mood swings, tearfulness, and mild depression that occur in up to 80 percent of new mothers, often within the first week after delivery.

This can make it difficult to decide how often and when to screening for PPD. Screening immediately after delivery may be less accurate, but may also improve access to psychiatric care. Screening just once after delivery may miss cases of PPD that develop later—up to one year after delivery. Women who don't experience PPD after their first pregnancy still need screening after subsequent pregnancies.

Several highly accurate questionnaires for PPD screening are available. The most commonly used tools, such as the Edinburgh Postnatal Depression Scale, can be used in a wide range of settings and take just a few minutes to perform. Other tools can provide accurate screening for PPD in just two questions.

Screening may be performed at clinics, doctor's offices, or other settings that that provide care to pregnant women and their families. The pediatrician's office has been suggested as the "most logical and readily available setting"—although it may be challenging to carry out screening at routine well-baby visits. Dr. Smith and colleagues emphasize the need for close attention to new mothers with a past history of depression, in whom PPD risk increases to 25 percent.

Once PPD is suspected or recognized, referral for mental health evaluation and management is essential. Treatment may include psychotherapy, which the authors believe is a "reasonable option" for mild depression; and/or medication, which they recommend for women with moderate to severe symptoms.

"Postpartum depression screening is recognized to be important for detection, feasible to carry out across locations, and useful in facilitating early diagnosis and treatment for women," Dr. Smith and colleagues conclude. They urge psychiatrists to be familiar with the screening approaches used in their area, and to be alert for possible depression in pregnant women and those with recent delivery.

"When used alone, screening does not increase the likelihood that women will receive treatment and follow-up," the researchers add. They highlight the need for further studies aimed at improving follow-up and treatment retention after diagnosis of PPD.

Click here to read “Postpartum Depression Screening: A Review for Psychiatrists.”

Article: “Postpartum Depression Screening: A Review for Psychiatrists” (doi: 10.1097/HRP.0000000000000103)

About the Harvard Review of PsychiatryThe Harvard Review of Psychiatry is the authoritative source for scholarly reviews and perspectives on a diverse range of important topics in psychiatry. Founded by the Harvard Medical School Department of Psychiatry, the journal is peer-reviewed and not industry sponsored. It is the property of Harvard University and is affiliated with all of the Departments of Psychiatry at the Harvard teaching hospitals. Articles encompass all major issues in contemporary psychiatry, including (but not limited to) neuroscience, psychopharmacology, psychotherapy, history of psychiatry, and ethics.

About Wolters KluwerWolters Kluwer is a global leader in professional information services. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.

Wolters Kluwer reported 2015 annual revenues of €4.2 billion. The group serves customers in over 180 countries, and employs over 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).

For more information about our products and organization, visit www.wolterskluwerhealth.com, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.